Search the reference library

D. Preclinical / non-clinical documentation — the three operational questions

Sponsors almost always over-scope the preclinical stack. A full non-clinical package for a small molecule runs 2,000–8,000 pages of GLP toxicology, pharmacology, and ADME reports. Whether that stack has to be rendered into Portuguese — a…

D. Preclinical / non-clinical documentation — the three operational questions

Mexico is the jurisdiction where sponsors most often assume the worst case — full perito traductor certification of the entire non-clinical stack — and pay for it. The statute is narrower than the assumption.

D. Preclinical / non-clinical documentation — the three operational questions

Colombia's preclinical answer is asymmetric: the drug pathway and the device pathway do not treat the same document the same way, and the legal-document rule is stricter than either.

D. Preclinical / non-clinical documentation — the three operational questions

Argentina is the strictest of the seven on legal instruments and, at the same time, offers one of the cleanest carve-outs for technical and preclinical reports. Getting the two apart is the entire exercise.

D.1 Do we have to translate every page of the preclinical stack?

No. RDC 947/2024 carries the verbatim exemption that governs the whole question:

D.1 Do we have to translate every page of the preclinical stack?

No. Article 153 of the Reglamento de Insumos para la Salud (RIS) scopes sworn translation to documents issued by a foreign authority: foreign marketing authorizations, certificates of free sale, GMP certificates, apostilled corporate ins…

D.1 Do we have to translate every page of the preclinical stack?

Rarely. Circular 5000-0001-22 §II.1 contains the concession sponsors most often miss: graphs and diagrams require no translation. Figures, chromatograms, dose-response curves, histopathology plates, and schematic diagrams inside a study …

D.1 Do we have to translate every page of the preclinical stack?

No — Art. 3(e) of Disposición 727/2013 provides an authenticated-copy carve-out for technical and preclinical reports. The sponsor files an authenticated copy of the report rather than a Colegio-legalized sworn translation of it. GLP tox…

D.1 Do we have to translate every page of the preclinical stack?

No — and Chile goes further than any peer. Art. 52(2) DS 3/2010 permits bibliography substitution for well-known active ingredients: for actives with established scientific literature, published bibliography stands in place of a sponsor-…

D.1 Do we have to translate every page of the preclinical stack?

No. Comunicado 008-2022-DIGEMID accepts English for CTD Modules 3, 4, and 5 outright. Module 4 is the entire non-clinical body of evidence: GLP toxicology, pharmacology, ADME, toxicokinetics. Module 3 covers quality and CMC; Module 5 the…

D.1 Do we have to translate every page of the preclinical stack?

Drugs under RTCA 11.03.59:18: Central American harmonized regime with Anexo 2 Mutual Recognition across Guatemala, Honduras, Nicaragua, Costa Rica, and Panama — a compliant SRS drug dossier becomes a regional launchpad. Preclinical modul…

D.1 Do we have to translate every page of the preclinical stack?

The honest answer depends on which pathway the document is filed into, and Panamá's two pathways do not sit at the same level of legal certainty.

D.1 Do we have to translate every page of the preclinical stack?

No, not the full text of Module 4. IE-B.3.2.1-MG-01 v4.0 §2 num. 2 accepts drug técnica-analítica and galénica documentation "en idioma castellano o inglés", and its Module-2 carve-out reaches only medicamentos nuevos — not the Module 4 …

D.1 Do we have to translate every page of the preclinical stack?

For clinical trial authorisation — yes, in full, in Spanish AND in the original language.

D.1 Is full-text translation of the entire preclinical CTD (Module 4) required?

No — and Costa Rica gives an unusually clear regulatory basis for saying so. The answer differs by pathway, and both pathways stop well short of full Module 4 translation.

D.1. Does preclinical need to be translated in the DR? YES — at the decree level.

Yes. Decreto 246-06 Art. 39 requires that scientific reports supporting a medicines registration be filed in Spanish or accompanied by a Spanish translation. That article names — by name — estudios toxicológicos and estudios farmacológic…

D.2 If translation IS required — is it text-only or does it require desktop publishing (DTP)?

D.2 If translation IS required — is it text-only or does it require desktop publishing (DTP)?

Where Panamá requires Spanish for a technical document, it requires format-faithful Spanish, and several provisions make that explicit rather than implied. Our posture is unchanged from the rest of our LATAM practice: text-only substance…

D.2 If translation IS required — is it text-only or does it require desktop publishing (DTP)?

It requires DTP. The Ecuador preclinical translation ask is not a prose translation; it is a structured-document reconstruction. Four textual hooks force the DTP posture:

D.2 If translation IS required — is it text-only or does it require desktop publishing (DTP)?

Paraguay requires format-faithful Spanish where the underlying document has structure — and in most Paraguay deliverables, it does.

D.2 If translation IS required — is it text-only, or does it require DTP?

Where Portuguese is mandatory, ANVISA usually also cares about the visual object, not just the words. RDC 751/2022 Art. 10 §9 requires device labelling and instructions for use in Portuguese as they will appear to the Brazilian user — me…

D.2 If translation IS required — is it text-only, or does it require DTP?

Text-only for everything in the perito tier — foreign authority documents are certified as running text with the perito's name, credential number, signature, and date. DTP applies elsewhere: Spanish labelling, IFU, and patient-facing mat…

D.2 If translation IS required — is it text-only, or does it require DTP?

For legal documents, text-only but cumulative. Concepto 174/2023 establishes that the requirements for foreign legal documents are cumulative and non-waivable: apostille and official translation and, where applicable, consular legalizati…

D.2 If translation IS required — is it text-only, or does it require DTP?

Text-only for the sworn tier, but with a procedural chain: apostille on the source document, sworn translation, Colegio legalization of the translation, then filing. Each link is separately verifiable and separately rejectable.

D.2 If translation IS required — is it text-only, or does it require DTP?

Two distinct obligations. Clinical research is bilingual by instruction: ISP guidance SDM/001 together with Resolución Exenta 5161/2016 requires the protocol and Investigator's Brochure in both English and Spanish. That is a text-only bu…

D.2 If translation IS required — is it text-only, or does it require DTP?

Text-only for administrative and legal documents. DTP for labelling, inserts, and IFU. The trap in Peru is not format — it is currency. DS 016-2011-SA Art. 28 imposes a two-year validity limit on foreign documents: a certificate of pharm…

D.2 Scope of the "DTP" — what preclinical content actually has to be delivered

Costa Rica does not use the term DTP. The functional equivalent resolves differently on each pathway.

D.2. The DR bilingual filing architecture — what it looks like in practice.

Art. 39 gives sponsors two paths: (i) file entirely in Spanish, or (ii) file the English original accompanied by a Spanish translation. The overwhelming majority of foreign sponsors take path (ii), which we call bilingual filing. Bilingu…

D.3 If translation is NOT required — what substitutes for it?

Something always substitutes. In Brazil the substitutes are: a Portuguese non-clinical overview that maps each source study to the claim it supports; a cross-reference index in Portuguese so the reviewer can navigate an English body of e…

D.3 If translation is NOT required — what substitutes for it?

Three substitutes carry Mexican filings: (1) a Spanish non-clinical overview per study, signed off under the responsable sanitario endorsement; (2) CTD Module 2.4 / 2.6 in Spanish over an English Module 4; (3) a Spanish study-index table…

D.3 If translation is NOT required — what substitutes for it?

A Spanish non-clinical summary per study, a Spanish caption and legend layer over retained English figures, and a Spanish cross-reference index into the English technical file. For devices, a Spanish essential-principles conformity table…

D.3 If translation is NOT required — what substitutes for it?

An authenticated copy under Art. 3(e), accompanied by a Spanish study-level summary and an index that ties each report to the safety conclusion it supports. For device filings, a Spanish essential-requirements table over untranslated eng…

D.3 If translation is NOT required — what substitutes for it?

Curated bibliography under Art. 52(2) for well-known actives; an officer-signed Spanish rendering for legal documents under Art. 29 No. 10; and a Spanish non-clinical overview referencing the English study reports. Chile's substitute is …

D.3 If translation is NOT required — what substitutes for it?

For Modules 3/4/5, nothing needs to substitute — the English text is the accepted filing. What still adds value is a Spanish Module 2 overview and summary set so the evaluator can navigate, and a Spanish document-currency register listin…

D.3 If translation is NOT required — what substitutes for it?

El Salvador's answer is the most flexible in the region for device preclinical because of the ISO 15223-1 symbology substitution at §6.3.4.d. Amavita's recommended format:

D.3 If translation is NOT required — what substitutes for it?

Panamá names the substitute in its own words: a Spanish evidence layer. It has three components, and it is the same architecture we deploy across the region.

D.3 If translation is NOT required — what substitutes for it?

For every drug that is not nuevo, CTD is optional (§2 num. 8) and the preclinical stack may be filed in English técnica-analítica format. What substitutes for translation are three ARCSA expectations:

D.3 If translation is NOT required — what substitutes for it?

For the clinical-trial pathway, translation is required for the IB and protocol regardless — there is no substitute. The market-access side has narrower substitution pockets and Amavita builds them where Paraguay's instructivos are expli…

D.3 What substitutes for full-text translation — four mechanisms

Instrument. Decreto Ejecutivo N.° 39433-S of 9 November 2015, reformed by Decreto 40084 of 3 October 2016 and by Decreto 44251 of 16 October 2023 (full text).

D.3. Three narrow substitution mechanisms — and why two don't help you.

Sponsors sometimes ask whether any Dominican rule permits substituting a summary, a foreign-agency assessment, or a reduced translation for the full preclinical file. There are three narrow mechanisms.

D.4 Consolidated preclinical instruction table

Not in the toxicology binder. Sponsors lose money translating 4,000 pages ANVISA never asked for, and lose cycles by under-translating the twelve pages of legal instruments ANVISA will not accept in English. The second exposure is curren…

D.4 Consolidated preclinical instruction table

D.4 Consolidated preclinical instruction table

In the cumulative rule, not the study reports. The §II.1 figure concession is real money saved; Concepto 174/2023 is real time lost when a sponsor treats apostille and official translation as alternatives. The device-vs-drug asymmetry is…

D.4 Consolidated preclinical instruction table

In the 2025 clinical expansion, not the preclinical stack. Sponsors working from a pre-2025 scope keep the IB in English and get an observación; sponsors who fear Art. 8 translate toxicology reports that Art. 3(e) lets them file as authe…

D.4 Consolidated preclinical instruction table

In the bilingual clinical requirement and the ICF readability threshold — not in toxicology. Sponsors budget for sworn translation Chile never asked for, then miss that the protocol and IB must exist in both languages and that a syntacti…

D.4 Consolidated preclinical instruction table

D.4 Consolidated preclinical instruction table

D.4 Consolidated preclinical instruction table

D.4 Consolidated preclinical instruction table

Read across the preclinical stack, the enacted texts sort as follows.

D.4 Consolidated preclinical instruction table

D.4 Consolidated preclinical instruction table

D.4. Consolidated DR preclinical table.

D.4.1 The preclinical evaluation criterion inside the Manual itself

Separately from the DIGEMAPS decree-level bilingual-filing rule in Decreto 246-06 Art. 39, CONABIOS's own Manual carries a scientific-validity criterion that reviewers apply when the file is opened: Manual V2 §4.3(e)(2) requires the ethi…

D.5 Where the preclinical translation risk actually sits

The common defect is conflating traducción oficial scope with technical-document scope. Sponsors sometimes pay for traducción oficial of biocompatibility reports (unnecessary; SRS accepts them in English with Spanish summary) or file leg…

D.5 Where the preclinical translation risk actually sits

The clinical-trial pathway carries more translation-scope risk than market access, and the asymmetry is textual, not anecdotal. On the market-access side the sponsor is protected by a statute — Ley 419 Art. 33 — plus a confirming reglame…

D.5 Where the preclinical translation risk actually sits

The risk is in the Módulo 2 tables, not in the Módulo 4 prose. A sponsor who plans an Ecuador medicamento nuevo filing as an English Module 4 exercise plus a Spanish "summary" underestimates the actual deliverable. The ICH M4S(R2) tabula…

D.5 Where the preclinical translation risk actually sits

The clinical-trial pathway carries the highest translation-scope risk in Latin America, and the risk is textual — not anecdotal, not reviewer-discretion. Paraguay is the single country in Amavita's LATAM library where the answer to "do w…

D.5 Where the submission risk actually sits

Not in the volume of preclinical translation. In five places.

D.5. The ten risks of getting DR preclinical wrong.

The DR is the country where Section D is not a summary — it's a full bilingual dossier obligation, decree-level enforced. Below are the ten risks Amavita audits for on every DR preclinical intake.

D.6 The institutional-committee layer that DE 21 does not fully expose

DE 21/2026 sits on top of an institutional-committee layer that carries most of the operational translation burden — and that layer is where the CBI, not the CNBI, sets the rules that a sponsor must actually meet. Two DE 21 articles turn…

D.7 DE 21 Art. 102 — LATAM's only explicit preclinical GLP article

Panamá is the only Central-American jurisdiction that names GLP inside its research decree. DE 21 Art. 102 (verbatim):

Preclinical Translation Across 19 LATAM Countries

What LATAM regulators and ethics committees actually require translated for the preclinical annex of clinical trial filings — 19 countries, 5 exceptions named.

Preclinical Translation Requirements Across 9 LATAM Regulators

What ANVISA, COFEPRIS, INVIMA, ANMAT, ARCSA and the rest actually require for Module 4 nonclinical documentation — tier by tier, with the conservative default when guidance is silent.

Section D. Preclinical / non-clinical documentation

No — and Costa Rica gives an unusually clear regulatory basis for saying so. The answer differs by pathway, and both pathways stop well short of full Module 4 translation.

Section D. Preclinical / non-clinical documentation — the three operational questions

Chile is the cheapest of the seven to translate correctly and the easiest to overspend on, because its permissive rules look too permissive to be true.

Section D. Preclinical / non-clinical documentation — the three operational questions

Peru has the most explicit English-acceptance rule of the seven and the least forgiving document-currency rule. Both facts change the preclinical scope.

Section D. Preclinical / non-clinical documentation — the three operational questions

A preclinical package for a single drug or device program routinely runs 800–3,500 pages: pharmacology, PK/ADME, toxicology, safety pharmacology, biocompatibility (for devices), and their appendices. El Salvador operates within the Centr…

Section D. Preclinical / non-clinical documentation — the three operational questions

A preclinical package for a single drug or device program routinely runs 800–3,500 pages: pharmacology, PK/ADME, toxicology, safety pharmacology, biocompatibility, electrical safety, sterilisation validation, and their appendices. Panamá…

Section D. Preclinical / non-clinical documentation — the three operational questions

Ecuador is a split-confidence jurisdiction for preclinical translation: the answer to "must we translate every page of the preclinical stack?" is no for the Module 4 prose body, and yes for a tightly defined subset of Module 2 tabulated …

Section D. Preclinical / non-clinical documentation — the three operational questions

A preclinical package for a single drug or device program routinely runs 800–3,500 pages: pharmacology, PK/ADME, toxicology, safety pharmacology, biocompatibility, electrical safety, sterilisation validation, and their appendices. Every …

Section D. Preclinical Translation Requirements — The Full Answer

This is the section of the guide most sponsors skip to. Because Amavita positions itself as the source of truth for Latin American preclinical translation posture, we walk it in five parts.

The two regulatory pathways trigger different translation obligations

Every LATAM regulator operates two related but separate regulatory pathways for a sponsor's product: (1) clinical-trial authorization, which is what allows the investigational product to enter a clinical study on the sponsor's timeline; …

The two regulatory pathways trigger different translation obligations

Every LATAM regulator operates two related but separate regulatory pathways for a sponsor's product: (1) clinical-trial authorization, which is what allows the investigational product to enter a clinical study on the sponsor's timeline; …

The two regulatory pathways trigger different translation obligations

Every LATAM regulator operates two related but separate regulatory pathways for a sponsor's product: (1) clinical-trial authorization, which is what allows the investigational product to enter a clinical study on the sponsor's timeline; …

The two regulatory pathways trigger different translation obligations

Every LATAM regulator operates two related but separate regulatory pathways for a sponsor's product: (1) clinical-trial authorization, which is what allows the investigational product to enter a clinical study on the sponsor's timeline; …

The two regulatory pathways trigger different translation obligations

Every LATAM regulator operates two related but separate regulatory pathways for a sponsor's product: (1) clinical-trial authorization, which is what allows the investigational product to enter a clinical study on the sponsor's timeline; …

The two regulatory pathways trigger different translation obligations

Every LATAM regulator operates two related but separate regulatory pathways for a sponsor's product: (1) clinical-trial authorization, which is what allows the investigational product to enter a clinical study on the sponsor's timeline; …

The two regulatory pathways trigger different translation obligations

Every LATAM regulator operates two related but separate regulatory pathways for a sponsor's product: (1) clinical-trial authorization, which is what allows the investigational product to enter a clinical study on the sponsor's timeline; …

The two regulatory pathways trigger different translation obligations

Panamá, like every LATAM regulator, operates two related but separate pathways for a sponsor's product: (1) clinical-trial authorization, which lets the investigational product enter a study on the sponsor's timeline; and (2) market-acce…

The two regulatory pathways trigger different translation obligations

Ecuador's preclinical translation obligation depends on the pathway, and the pathway depends on the product classification. The table below reconciles the four regimes side by side.